Neuroblastoma clinical trials

Explore recruiting neuroblastoma clinical trials.

Recruiting neuroblastoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuroblastoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

Spain, France, Denmark, Ireland, Germany

Phase II and Phase III (Integrated) EU CTIS Study details

J1O-MC-JZHD: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours

Spain, Germany, Czechia, Hungary, France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors

Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN : Randomised, international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma, and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy

Netherlands, Spain, Denmark, Norway, Germany, Czechia +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Denmark, France, Germany, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Neuroblastoma trials by city

Neuroblastoma in Toronto Neuroblastoma in Vancouver Neuroblastoma in Montreal Neuroblastoma in Calgary Neuroblastoma in Edmonton Neuroblastoma in Ottawa Neuroblastoma in Winnipeg Neuroblastoma in Quebec City Neuroblastoma in Hamilton Neuroblastoma in Kitchener Neuroblastoma in London Neuroblastoma in Halifax Neuroblastoma in New York Neuroblastoma in Los Angeles Neuroblastoma in Chicago Neuroblastoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease